PharmacoEconomics & Outcomes News 340 - 24 Nov 2001 ■ Patients with end-stage heart failure who are fitted with a left ventricular assist device achieve an increased survival benefit and have an improved quality of life (QOL), report US-based researchers. Between 1998 and 2001, 129 patients with chronic end-stage heart failure were randomised to receive either a left ventricular assist device (n = 68) or optimal medical therapy (61). Results showed that in the group that received the device, there was a 48% reduction in the risk of death from any cause, compared with the group that received optimal medical therapy. At 1 year, scores on the physical- function and emotional-role subscales of the Short- Form 36 were significantly better in the group that received left ventricular assist devices than in the medical therapy group. Rose EA, et al. Long-term use of a left ventricular assist device for end-stage heart failure. New England Journal of Medicine 345: 1435-1443, 15 Nov 2001 800876619 1 PharmacoEconomics & Outcomes News 24 Nov 2001 No. 340 1173-5503/10/0340-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Left ventricular assist device improves QOL in HF

Download PDF Report

Upload
ngokhuong
View
212
Download
0

Embed Size (px)

Citation preview

Page 1: Left ventricular assist device improves QOL in HF

PharmacoEconomics & Outcomes News 340 - 24 Nov 2001

■ Patients with end-stage heart failure who arefitted with a left ventricular assist device achieve anincreased survival benefit and have an improvedquality of life (QOL), report US-based researchers.Between 1998 and 2001, 129 patients with chronicend-stage heart failure were randomised to receiveeither a left ventricular assist device (n = 68) oroptimal medical therapy (61). Results showed that inthe group that received the device, there was a 48%reduction in the risk of death from any cause,compared with the group that received optimalmedical therapy. At 1 year, scores on the physical-function and emotional-role subscales of the Short-Form 36 were significantly better in the group thatreceived left ventricular assist devices than in themedical therapy group.Rose EA, et al. Long-term use of a left ventricular assist device for end-stageheart failure. New England Journal of Medicine 345: 1435-1443, 15 Nov2001 800876619